Molecular-based imaging provides new opportunities to assess vital cellular processes in vivo. The ability to monitor the molecular processes of cancer via non-invasive imaging may provide critical information regarding the effects of therapy. In the context of pre-clinical research, the use of in vivo imaging permits the acquisition of a complete dynamic biodistribution study in each animal, thereby reducing the number of animals required to reach a statistically adequate result;often the techniques used in small animal imaging are directly transferable to the clinical setting. The Small Animal Imaging Core (SAIC) is a new shared resource dedicated to providing investigators access to the state-of-the-art in small animal imaging capabilities for use in basic and translational research relevant to the mission of the City of Hope Cancer Center.
Specific aims of the SAIC include: (1) maintaining a thorough understanding of the current capabilities and limitations of small animal imaging as they pertain to cancer research;(2) implementing, developing, calibrating, maintaining, and operating relevant imaging systems within the context of a small animal imaging laboratory;and (3) optimizing the use of small animal imaging in research at City of Hope by consulting with investigators. Core personnel currently include a Director, an imaging physicist, and a manager, all of whom are highly experienced in the use of imaging for research with animals. Small animal imaging systems in operation include two units for bioluminescence optical imaging (I VIS 100, Xenogen Corp.);a gamma camera (Y IMAGER, Biospace, Inc.);a PET scanner (microPET R4, CTIMI, Inc.);and a CT scanner (microCAT II Hi Res, CTIMI, Inc.). The microPET and microCAT are readily used in tandem to generate co-registered functional-anatomic PET/CT images. The Animal Resources Center has provided four rooms within the Parvin Biomedical Research Building for use by the animal imaging program (one room for the microPET, microCAT, and the y-IMAGER;two rooms for the Xenogen MS machines;and one room for a gamma counter). A system has been developed for billing users for a portion of the costs of the imaging procedures. During the first 12-month reporting period, the SAIC was used by 13 Cancer Center members from 3 Research Programs and peer-reviewed usage represented 89% of total usage. Annual budget for the core is $165,922 (97% institution, 3% chargebacks);42% ($70,000) is being requested from the CCSG.
|Gu, Ying; Zhang, Jiawei; Ma, Xiaoxiao et al. (2017) Stabilization of the c-Myc Protein by CAMKII? Promotes T Cell Lymphoma. Cancer Cell 32:115-128.e7|
|Cao, Pengpeng; Mooney, Rachael; Tirughana, Revathiswari et al. (2017) Intraperitoneal Administration of Neural Stem Cell-Nanoparticle Conjugates Targets Chemotherapy to Ovarian Tumors. Bioconjug Chem 28:1767-1776|
|Mohanty, Suchismita; Mohanty, Atish; Sandoval, Natalie et al. (2017) Cyclin D1 depletion induces DNA damage in mantle cell lymphoma lines. Leuk Lymphoma 58:676-688|
|Wittenberg, Elaine; Ferrell, Betty; Koczywas, Marianna et al. (2017) Pilot Study of a Communication Coaching Telephone Intervention for Lung Cancer Caregivers. Cancer Nurs :|
|Yuan, Yuan; Vora, Nilesh; Sun, Can-Lan et al. (2017) Association of Pre-Chemotherapy Peripheral Blood Pro-Inflammatory and Coagulation Factors with Physical Function in Women with Breast Cancer. Oncologist 22:1189-1196|
|Deng, Ruishu; Hurtz, Christian; Song, Qingxiao et al. (2017) Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease. Nat Commun 8:978|
|He, Zhiheng; Ma, Jian; Wang, Ruiqing et al. (2017) A two-amino-acid substitution in the transcription factor ROR?t disrupts its function in TH17 differentiation but not in thymocyte development. Nat Immunol 18:1128-1138|
|Kortylewski, Marcin; Moreira, Dayson (2017) Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities. Cancer Immunol Immunother 66:979-988|
|Somlo, George; Frankel, Paul H; Arun, Banu K et al. (2017) Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res 23:4066-4076|
|Slavin, Thomas P; Neuhausen, Susan L; Nehoray, Bita et al. (2017) The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes. Fam Cancer :|
Showing the most recent 10 out of 1277 publications